Teva's Stock Surges 1.95% on Strong Earnings and Institutional Buys Ranks 418th in NYSE Trading Volume Amid Strategic Blackstone Partnership

Market Snapshot

Teva Pharmaceutical Industries (TEVA) closed with a 1.95% increase on March 4, 2026, marking a notable rise despite moderate trading volume. The stock’s trading value for the day reached $0.31 billion, ranking 418th in terms of activity on the New York Stock Exchange. This performance follows a recent surge in institutional and hedge fund activity, with key investors bolstering their positions. The stock’s market capitalization stands at $38.83 billion, with a price-to-earnings (PE) ratio of 28.14 and a beta of 0.72, reflecting a relatively low volatility profile compared to the broader market.

Key Drivers

The upward movement in Teva’s stock is primarily attributed to a combination of strong earnings results, strategic partnerships, and growing institutional confidence. On January 28, 2026, Teva reported first-quarter earnings per share (EPS) of $0.96, significantly outperforming the $0.65 consensus estimate. Revenue reached $4.71 billion, surpassing the $4.36 billion forecast, driven by an 11.4% year-over-year revenue increase. The company’s return on equity (46.28%) and net margin (8.16%) further underscored its operational efficiency. These results have reinforced investor optimism, particularly as Teva reiterated its FY 2026 guidance of 2.570–2.770 EPS, aligning with analysts’ expectations of 2.5 EPS for the year.

Institutional investor activity has also played a pivotal role in supporting the stock’s momentum. The Teachers Retirement System of Kentucky increased its stake in Teva by 4.3% during the third quarter, holding 2.61 million shares valued at $52.75 million as of its latest SEC filing. Other hedge funds, including JFS Wealth Advisors LLC and Rothschild Investment LLC, substantially raised their positions, with JFS’s stake growing by 257.1% and Rothschild’s by 97%. These moves highlight institutional confidence in Teva’s long-term prospects, particularly as 54.05% of the stock is now owned by hedge funds and institutional investors.

Analyst sentiment has further bolstered the stock’s appeal. In late January and December 2025, major firms such as Piper Sandler, JPMorgan, and Truist Financial raised their price targets for Teva, with Piper Sandler elevating its target to $40 from $30 and assigning an “overweight” rating. Barclays and Scotiabank also upgraded their recommendations, with the latter giving the stock a “sector outperform” rating. The consensus rating among analysts is “Moderate Buy,” supported by an average price target of $37.56, which is 11.4% above the closing price on March 4. This analyst optimism reflects confidence in Teva’s ability to capitalize on its generic drug portfolio and specialty branded products, including its migraine treatment Ajovy and schizophrenia medication Uzedy.

A strategic partnership with Blackstone Life Sciences has added another layer of growth potential. Teva secured a $400 million investment from Blackstone to develop duvakitug, a late-stage gut disease drug in Phase 3 trials. The deal, which includes milestone payments and royalties contingent on FDA approval, is expected to offset a portion of Teva’s R&D expenses, which exceeded $1 billion in 2025. While the drug faces competition from similar therapies in development by Merck and Roche, the partnership underscores Teva’s pivot toward innovation, contrasting with past challenges stemming from the loss of patent protections for its flagship MS drug, Copaxone, in 2018.

However, insider selling has introduced some caution. The company’s CFO, Eliyahu Sharon, sold 345,810 shares for $11.6 million, reducing his stake by 85.75%. While such sales do not always signal bearish sentiment, they may raise questions about management’s confidence in the stock’s near-term trajectory. Additionally, other executives, including CAO Amir Weiss and VP Richard Daniell, have liquidated significant portions of their holdings in recent months, further highlighting the mixed signals in the market.

Collectively, these factors—strong earnings, institutional backing, analyst upgrades, and strategic R&D partnerships—have driven Teva’s stock higher, despite insider sales and competitive pressures in its key therapeutic areas. The company’s ability to sustain its growth momentum will depend on the success of its pipeline, including duvakitug, and its capacity to maintain profitability in a sector marked by pricing pressures and regulatory challenges.